Why Direct Compression of Aliskiren Hemifumarate Requires Compaction Force Mapping

Aliskiren hemifumarate lots received at a tableting site are first tested for moisture sorption at 25 °C/60% RH and 40 °C/75% RH before direct compression is selected. Direct compression is chosen only when the API median particle size (Dv50, laser diffraction per USP <429>) is maintained between 150 µm and 250 µm, and the fines fraction below 45 µm is held under 20% w/w to avoid feeding ratholing in the hopper. On a rotary tablet press equipped with B-tooling and 16 stations, the compaction force required to achieve a tablet hardness of 60–80 N may fall in the 8–14 kN range, while larger 300 mg dose tablets require 20–30 kN on a production press. Ejection stress is monitored because aliskiren hemifumarate can adhere to stainless steel punches when lubrication is below 0.5% w/w magnesium stearate; lubricant levels above 1.0% w/w delay disintegration beyond 15 min and reduce tensile strength. The blend is compacted into round convex tablets with a target weight of 150 mg or 300 mg aliskiren base, then film-coated with an aqueous hydroxypropyl methylcellulose/polyethylene glycol system to improve swallowability and mask surface roughness. In-process controls are set at ±5% for average weight, not more than 1.0% for friability per USP <1216>, and disintegration time no more than 30 min in 0.1 M hydrochloric acid. Tablet breaking force is recorded per USP <1217>; process capability analysis is required when hardness values fall below 50 N because edge chipping increases during coating pan rotation. Dissolution testing per USP <711> Apparatus II at 50 rpm in pH 4.5 acetate buffer is used to verify lot-to-lot equivalence; the acceptance range is established from clinical batch dissolution profiles and is not a fixed single-point Q value.

Before a fixed-dose combination with hydrochlorothiazide is compressed into a bilayer or monolayer tablet, the particle-size distribution of aliskiren hemifumarate and hydrochlorothiazide must be matched within a Dv50 ratio of 0.75–1.25 to prevent segregation during blending and transfer. Hydrochlorothiazide is a low-permeability, practically insoluble diuretic with a different compressibility profile; when combined with aliskiren, the direct blend is usually replaced by wet granulation using a starch paste or hypromellose binder solution at a binder concentration of 2–5% w/w of the dry granulation. Granulation is performed in a high-shear mixer at an impeller speed of 150–250 rpm and a chopper speed of 1,500–3,000 rpm, followed by fluid-bed drying at an inlet air temperature of 50–60 °C until the loss on drying reaches 1.0–2.5% w/w as measured by halogen moisture balance. The dried granules are milled through a 1.0 mm screen and lubricated with 0.5% w/w magnesium stearate. If a bilayer tablet is selected, the first layer is pre-compressed at 4–6 kN and the second layer is applied at a main compression force of 18–25 kN; the interface must be examined for cracks because the two active layers exhibit different elastic recovery after decompression. The finished dosage form is a film-coated tablet containing 150/12.5 mg, 150/25 mg, 300/12.5 mg, or 300/25 mg aliskiren/hydrochlorothiazide, with release testing that includes two dissolution profiles: aliskiren in pH 4.5 acetate buffer and hydrochlorothiazide in 0.1 M hydrochloric acid using USP <711> Apparatus II at 50 rpm. Compliance with ICH Q3C residual solvent limits requires verification that the binder solvent, if organic, remains below the option-2 limits for Class 3 solvents; aqueous granulation is generally preferred to avoid residual ethanol or isopropanol.

Aliskiren Capsule Filling on High-Speed Dosator Machines

When aliskiren hemifumarate is encapsulated on a high-speed dosator machine, the neat API is rarely suitable for direct powder filling because of electrostatic charge and poor flow through the dosator nozzles. The granulation is performed on a fluid-bed granulator with a 5 kg batch size and a top-spray insert; the binder solution is an aqueous hypromellose 6 cP solution at 5% w/w solids, sprayed at a rate of 10–15 g/min with atomizing air pressure of 1.5–2.0 bar. The granule is dried to a moisture content of 1.0–2.0% w/w and sized through a 0.8 mm conical mill before blending with 0.5% w/w magnesium stearate and 1% w/w colloidal silicon dioxide. The finished powder blend is filled into size 1 hard gelatin capsules at a target fill weight that provides 150 mg aliskiren base per capsule, with an automatic capsule filling machine operating at 60,000–80,000 capsules/h; dosator height is adjusted so that the fill weight relative standard deviation remains below 2.0%. In-process checks include average fill weight at ±4% of target, individual fill weight outside the 90–110% limit not exceeding 2 capsules in 20, and capsule opening/join defects below 0.5%. Disintegration time is tested per USP <701> with distilled water at 37 ± 2 °C; the capsule shell should disintegrate within 15 min, but release from the aliskiren granules is confirmed by dissolution testing in pH 4.5 acetate buffer. Capsule products are packaged in HDPE bottles with desiccant when stability data show moisture-induced hydrolysis of the hemifumarate salt at 40 °C/75% RH; the moisture barrier requirement is verified by USP <671> for plastic packaging systems.

For patients who cannot swallow intact tablets, aliskiren hemifumarate is converted into an oral granule intermediate for sachet packaging by top-spray fluid-bed granulation at a defined spray rate, exhaust air temperature, and dew point. In this process, the API is preblended with mannitol and crospovidone in a 60%:35%:5% ratio, and granulated with a 4% w/w hypromellose E5 or povidone K30 aqueous binder solution. The inlet air temperature is held at 55–65 °C, the product temperature at 32–38 °C, and the spray rate at 8–12 g/min for a 3 kg batch; the filter bag is purged every 5 min to prevent blinding from hygroscopic fines. After drying to residual moisture below 1.5% w/w, the granules are sieved through a 1.0 mm screen and filled into aluminium foil sachets at a dose of 75 mg or 150 mg aliskiren base. Each sachet also contains 0.2% w/w silicon dioxide as anti-caking agent and a flavour system that is added after granulation to avoid thermal degradation. In-process limits include granule bulk density 0.45–0.60 g/mL, tapped density 0.55–0.75 g/mL, and Hausner ratio below 1.35 measured per USP <616>. Sachet filling is performed on a vertical form-fill-seal line with a dust extraction system; seal integrity is tested at 300–500 mbar differential pressure after filling. The granules are dispersed in 30 mL water before administration, and the resulting suspension must pass through a 0.9 mm sieve to meet dosing uniformity expectations. Dissolution is carried out in USP <711> Apparatus II at 50 rpm in 0.1 M hydrochloric acid because the granules are intended for pre-gastric release; the sachet product must also meet USP <905> uniformity of dosage units with an acceptance value of not more than 15.

If Injectable Administration Is Required, Terminal Sterilization and pH Drift Govern Feasibility

An injectable aliskiren formulation is not an established commercial dosage form, so downstream development follows the contaminant-control and stability logic of USP <1> injections. The hemifumarate salt is dissolved in Water for Injection at a concentration equivalent to 10 mg/mL aliskiren base, and the pH is adjusted to 4.0–5.0 with dilute hydrochloric acid or sodium hydroxide; below pH 3.0, the risk of acid-catalysed hydrolysis increases, while above pH 6.0, the solubility of the free base must be confirmed by phase-solubility analysis because ionization decreases with rising pH. The solution is filtered through a 0.22 µm polyvinylidene fluoride membrane and filled into Type I borosilicate glass vials under ISO 14644-1 Class 5 laminar airflow as required by EU GMP Annex 1. Terminal sterilization is preferred over aseptic filtration only when the formulation remains stable after an autoclave cycle at 121 °C for 15 min or 115 °C for 30 min; if terminal sterilization is not feasible due to drug degradation, the process must be validated as aseptic with media fills performed at least three times annually. For injectable use, the finished product is tested for bacterial endotoxins per USP <85> with a limit calculated from the maximum bolus dose, sterility per USP <71> using membrane filtration, particulate matter per USP <788> with limits of not more than 6,000 particles per container at ≥10 µm and not more than 600 particles per container at ≥25 µm for small-volume parenterals, and pH per USP <791> with a tolerance of ±0.5 unit. Osmolality is adjusted to 280–320 mOsm/kg with sodium chloride or mannitol per USP <785>. A lyophilized form, if required for long-term stability, is produced by fill-finish in 10 mL vials, freezing at −40 °C, primary drying at −20 °C shelf temperature for 48 h under vacuum, and secondary drying at 25 °C for 12 h; reconstitution with 2.5 mL Water for Injection gives a clear solution. Published stability data for this specific aliskiren injectable configuration is limited; therefore, accelerated stability studies per ICH Q1A at 40 °C/75% RH are not applicable and should be replaced with 25 °C/60% RH and 2–8 °C storage conditions.

Dry Granulation of Aliskiren–Amlodipine Bilayer Tablets Exposes Interlayer Elastic Recovery Limits

The combination of aliskiren hemifumarate with amlodipine besylate is typically processed by roller compaction because wet granulation introduces moisture that destabilizes amlodipine. The aliskiren layer is preblended with microcrystalline cellulose, crospovidone, and 0.5% w/w magnesium stearate, then compacted at a roll pressure of 40–60 bar and roll speed of 2–5 rpm. The milled granules have a Dv50 of 200–400 µm and a tapped density of 0.55–0.70 g/mL; the amlodipine besylate layer is processed separately because amlodipine degrades when exposed to heat above 60 °C and moisture above 60% RH. Bilayer compression is performed on a production rotary press with a precompression force of 2–5 kN for the first layer and a main compression force of 15–25 kN; the target hardness of the finished bilayer tablet is 80–120 N. The interface is inspected in-process using a vision system after every 30 min run; delamination can occur if the ratio of first-layer hardness to total tablet hardness exceeds 0.6. The finished tablet contains 150/5 mg or 300/10 mg aliskiren/amlodipine and is film-coated with a light-protective, opaque coating because amlodipine is photosensitive. Dissolution testing is performed in USP <711> Apparatus II at 75 rpm in 0.1 M hydrochloric acid for amlodipine and in pH 4.5 acetate buffer for aliskiren; both drugs must meet separate Q values established from biobatch and stability data. Compliance with ICH Q3D requires that the roller compactor contact parts be verified for elemental impurities after milling; the finished product is also tested for nitrosamine impurities per ICH M7 and regional guidance when secondary amines are present in the API synthesis.